Search Results

CDK4/6 Abemaciclib GEP-NETS << Back Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT03891784 DRUG/TREATMENT: abemaciclib PHASE: 2 STATUS: Recruiting SPONSOR: University of Washington Collaborator: Eli Lilly and Company Dr. Heloisa Soares Discusses CDK4/6 abemaciclib GEP-NETS DESCRIPTION: This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: David B. Zhen, MD Fred Hutch/University of Washington Cancer Consortium EMAIL : dbzhen@uw.edu

<< Go back to the Podcast page EPISODE 18: MENTAL HEALTH & NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. MEET DR. KAREN KERSTING Karen Kersting, PhD, is a licensed clinical psychologist who provides counseling and psychotherapy to patients treated by surgeons in the Division of Surgical Oncology at the Medical College of Wisconsin. She completed an undergraduate degree in Journalism at the University of Wisconsin—Madison, a PhD in Counseling Psychology at Virginia Commonwealth University in Richmond, VA, and a postdoctoral fellowship in clinical health psychology at the Dayton Veterans Administration Medical Center in Dayton, OH. She joined the faculty of MCW in 2016. Dr. Kersting’s research interests include the development and assessment of integrated psychosocial services for people coping with cancer diagnosis and treatment, with an emphasis on patients diagnosed with cancer of the pancreas. Additionally, her work aims to highlight issues related to social determinants of health and Acceptance and Commitment Therapy interventions. TOP 10 QUESTIONS 1. How common are mental health issues in NET patients? What are the most common mental health issues you see in NET and what can be done about it? 2. How does anxiety impact NET patients? Why is it so prevalent in these patients? When do I know I need to reach out for support with my anxiety? What does treatment for anxiety look like? 3. How does depression impact NET patients? 4. What kind of sleep problems do you see in NET patients? 5. How do you work with patients who have long periods of fatigue? 6. How can a psychologist help people who are struggling to eat after treatment? 7. How can a patient, loved one, or physician tell the difference between a symptom such as fatigue or anxiety caused by NET tumors vs. a psychological trigger? Does it matter? How does one’s mental health impact one’s NET disease or the effectiveness of treatments? 8. Discuss how NET may impact young adult NET patients? How does NET impact young adult children, teenagers, and young children of NET patients? 9. Who should see a psychologist? When should someone see a psychologist? How does one find a psychologist? What should a patient expect when they come for a first visit with a mental health professional such as a psychologist, therapist, social worker or other? 10. What coping strategies or advice do you have for NET patients? What coping strategies or advice for family members or loved ones? RESOURCES READ Acceptance and Commitment Therapy Dr. Kersting's Publications Elephant & Tea Magazine JOIN AYA Neuroendocrine Cancer Group (Young Adult Private Facebook Group) LACNETS RESOURCES Wellness Resources Resources for Children Grief Resources Caregivers DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM Download a Transcript of this Episode >> ABOUT THIS EPISODE In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. MEET DR. GUILLAUME PEGNA Dr. Guillaume (Will) Pegna, MD is a Medical Oncologist at Oregon Health & Science University or OHSU in Portland, Oregon. Dr. Pegna specializes in the care of adults with cancers of the gastrointestinal (GI) and neuroendocrine systems (NETs). He is additionally interested and experienced in the management of rare tumors including pheochromocytomas, paragangliomas, and adrenocortical carcinomas. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy, and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys. Dr. Pegna grew up in Upstate New York in a French-speaking family and goes by either Guillaume or Will, the English translation of his name. Outside of work, he enjoys hiking, ice hockey, and traveling with his family. TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM REFERENCES 10. Oral abstract presentation by Lindsay Hunter, MD, Huntsman Cancer Institute: "Circulating tumor DNA using a personalized, tumor-informed assay in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumor patients." 9. Oral abstract presentation by Mehran Taherian, MD, MD Anderson: "High-grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathology and Molecular Characteristics." 8. Oral presentation by Aman Chauhan, MD, University of Kentucky Markey Cancer Center: “How to Define PRRT Refractory and Role of PRRT Repeat?” NET RETREAT: A Phase II RCT of Lu-177 DOTATATE Retreatment vs. Everolimus in Midgut NET Courtesy of Aman Chauhan, MD 7. Oral presentation by Jaume Capdevila Castillon, MD, PhD, Hospital Universitari Vall d’Hebron, Spain: “Novel TKIs for GEP NETs” Courtesy of Jaume Capdevila MD, PhD Poster presentation by Satya Das, MD: "E fficacy and Toxicity of Anti-Vascular Endothelial Growth Factors (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) - A Systematic Review and Meta-Analysis." 6. Oral abstract presentation by Nancy Joseph, MD, PhD, University California, San Francisco: "TP53 Mutation Portends a Worse Overall Survival in Patients with Advanced Grade 3 Well-Differentiated Neuroendocrine Tumors." 5. Oral abstract presentation by Taymeyah Al-Toubah, MPH, Moffitt Cancer Center: "Phase 2 Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors." 4. Oral abstract presentation by Eleonora Pelle, MD, Moffitt Cancer Center: "Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors." 3. Oral abstract presentation by Taymeyah Al-Toubah, MPH, Moffitt Cancer Center: "Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate." 2. Oral abstract presentation by Brendon Herring, MS, University of Alabama at Birmingham School of Medicine: "Transcriptomic Influences of Racial Disparities in Black Patients with Pancreatic Neuroendocrine Tumors." Oral abstract presentation by Farhana Moon, Sr Clinical Research Analyst, UCSF, Helen Diller Family Comprehensive Cancer Center: "Variants of Uncertain Significance (VUS) are More Common in Non-Caucasian Patients with Neuroendocrine Neoplasms (NENs)." 1.Oral presentation by Dr Ebrahim Delpassand, Excel Diagnostics: "Early Data on 212Pb-DOTAMTATE (Alpha PRRT)" ABOUT NANETS The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 10 presentations from the NANETS October 27-29, 2022 Symposium, there are many more noteworthy abstracts found (or listed) here: Click here for NANETS Oral Abstracts Presentations Click here for NANETS Oral Abstracts in PDF format While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers. CLINICAL TRIAL INFORMATION Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (ALPHAMEDIX02) Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (CABINET) EXCEL Diagnostics (AlphaMedix, Alpha PRRT trial) RESOURCES "NET Medical Therapies" with Dr. Hecht (October 6, 2022) "Exciting Advances in NET Management: Cu64 DOTATATE & Alpha PRRT" with Dr. Ebrahim S. Delpassand DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Paltusotine in Carcinoid Syndrome << Back Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome CLINICALTRIALS.GOV IDENTIFIER: NCT05361668 DRUG/TREATMENT: Paltusotine PHASE: 2 STATUS: Recruiting SPONSOR: Crinetics Pharmaceuticals Inc. Update from the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland (March 5-7, 2025): Paltusotine_ENETS 2025 .pdf Download PDF • 356KB Dr. Aman Chauhan Discusses Paltusotine in Carcinoid Syndrome UPDATE: On Tuesday, March 12, 2 024, Crinetics Pharmaceuticals announced positive topline results from their Phase 2 study of Paltusotine, a once-daily pill, under investigation for the treatment of carcinoid syndrome. The results show that Paltusotine was generally well-tolerated and reduced the frequency and severity of bowel movements and flushing. The company plans to engage the FDA to initiate a P hase 3 trial by the end of 2024. To read the announcement, go to the March 12, 2024 press release . To view the live webcast discussing the data and slides, go to the Paltusotine Study Results Presentation . UPDATE: On Monday, December 18, 2023, Crinetics announced positive initial findings from their ongoing open-label phase 2 study of paltusotine for the treatment of carcinoid syndrome. Today's announcement states “These initial results show the potential of paltusotine to significantly reduce both frequency and intensity of bowel movements and flushing, the key carcinoid syndrome symptoms. Further, paltusotine was well-tolerated and the overall pharmacokinetic profile was consistent with prior studies. After completing this Phase 2 study next quarter, we anticipate sharing the results with the FDA to align on the design of a Phase 3 program.” To read the announcement, go to the December 18, 2023 press release . To view the slides from the announcement, go to the, " CRINETICS INITIAL FINDINGS FROM ONGOING OPEN-LABEL PHASE 2 STUDY OF PALTUSOTINE FOR THE TREATMENT OF CARCINOID SYNDROME " . UPDATE: On Sept 10, 2023, Crinetics Pharmaceuticals announced positive results for their paltusotine phase 3 acromegaly study. This is the same once-daily pill that is currently in a phase 2 study for NET patients with carcinoid syndrome. To read the announcement, go to https://crinetics.com/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/ . DESCRIPTION: Crinetics is sponsoring a phase 2 study to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Crinetics Clinical Trials EMAIL: clinicaltrials@crinetics.com PHONE: 833-827-9741

ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs << Back ACTION-1 ALPHA PRRT - Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT05477576 DRUG/TREATMENT: ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) for injection COMPARED TO: Everolimus, Sunitinib, Octreotide, Lanreotide PHASE: Phase 3 STATUS: Recruiting April 2023 SPONSOR: RayzeBio, Inc. Dr. Heloisa Soares discusses the ACTION-1 Trial Dr. Will Pegna discusses the ACTION-1 Trial Starting at 5:07 DESCRIPTION: RayzeBio is sponsoring the ACTION-1 study, a phase 3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC. Update - Aug 22, 2023 2023 ESMO Abstract shows preliminary safety and efficacy (Note: The meaning of efficacy in clinical trials refers to the capacity of a treatment, device, or medication, to produce a desired effect on the patient population.) Download the PDF here: 1198P-RYZ101-301-ESMO-2023-poster-UPLOAD .pdf Download PDF • 4.57MB For more information on eligibility criteria, trial locations, study details, etc ., go to ClinicalTrials.gov to view this trial here. CONTACT: RayzeBio Clinical Trials EMAIL: clinicaltrials@rayzebio.com PHONE: 619-657-0057

<< Back Immunotherapy Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas CHM-2101 CAR-T cell for GI Cancers DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC << Back Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC CLINICALTRIALS.GOV IDENTIFIER: NCT03647163 Drug/Treatment: VSV-IFNβ-NIS and Pembrolizumab PHASE: I/II STATUS: Recruiting Sponsor: Vyriad, Inc. Collaborator: Mayo Clinic Dr. Heloisa Soares Discusses Systemic VSV-IFNβ-NIS and Pembrolizumab DESCRIPTION: Vyriad is sponsoring the safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious. Thus, this study will test a second VSV-IFNβ-NIS dose level, 1.0x1011 TCID50. A safety assessment will be carried out after 3 patients are enrolled. If this dose schedule is well tolerated and virus PK are not negatively impacted, both the NSCLC and NEC expansion cohorts will open using this dose schedule. If 2 of the first 3 patients or 2 of the first 6 patients experience a DLT, the dose will be de-escalated to 5 x 1010. The safety run-in/dose escalation portion of this study is expected to require a minimum of 3 patients and a maximum of 18 patients (6 patients per dose level). The expansion portion of this study is expected to require a minimum of 10 per cohort. The NSCLC and NEC patients enrolled at the identified optimal dose in the dose escalation cohort would be included in the dose expansion cohort if they are evaluable for the primary endpoint in the expansion portion (4 dose escalation patients at the optimal dose are expected to roll over to the expansion). Therefore, the overall sample size details will be a maximum of 40 patients. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Jennifer Boughton EMAIL: JBoughton@vyriad.com PHONE: 908-553-3135 Shruthi Naik, PhD EMAIL: snaik@vyriad.com PRINCIPAL INVESTIGATOR: Julian R. Molina, MD, PhD Mayo Clinic

<< Go back to the Podcast page EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY Download a Transcript of this Episode >> ABOUT THIS EPISODE How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. MEET DR. ALEXANDRA GANGI Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. TOP 10 QUESTIONS 1. How do you decide if the tumors can and should be cut out? How does tumor location, tumor size, and amount of tumors factor into your decision? 2. How do you decide if someone should have a laparoscopic surgery versus open surgery? What about robotic surgery? 3. How do you decide whether or not to remove the ileocecal valve? 4. What work up should NET patients have before surgery? Should all NET patients have an echo? 5. What is the risk of carcinoid crisis with a dental procedure, a biopsy, or with surgery? How do you manage this? 6. Should NET patients be on somatostatin analogs before surgery? What about after surgery? If so, when would you restart it? 7. When would you want someone on chemotherapy or PRRT to shrink a tumor before surgery? When might you want to do surgery first followed by another treatment? 8. When would you recommend imaging after NET surgery? What type of imaging would you order? 9. Why are there differing opinions from NET specialists, specifically about surgery and what treatment should be offered as the next option? 10. What questions would you recommend NET patients ask at their surgical consultation? RESOURCES READ LACNETS Resources on Surgery Blog Practical Tips for Patients Preparing for Surgery NET VITALS NET Intro WATCH "Surgery for NETs" - Alexandra Gangi, MD, Cedars-Sinai - 2020 LACNETS Virtual NET Conference (June 23, 2020) "To Cut or Not to Cut? What Your NET Surgeon Wants You To Know" - Callisia Clarke, Medical College of Wisconsin - 2021 LACNETS Virtual NET Conference (June 19, 2021) "NET Surgery: Making Decisions & Preparing for Surgery" - Callisia Clarke, MD, Medical College of Wisconsin - 2022 LACNETS Virtual NET Conference (June 18, 2022) "Your Pathologist & Your Pathology Report" - Sue Chang, MD, City of Hope (March 27, 2020) "Pathology" - Alberto Marchevsky, MD, Director of Pathology, Cedars-Sinai - 2019 LACNETS Conference (June 8, 2019) LISTEN The LACNETS Podcast Episode 3: Surgery for NETs >> The LACNETS Podcast Episode 11: Pathology for NETs >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas << Back Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas IDENTIFIER ( ClinicalTrials.gov ) : NCT06041516 DRUG/TREATMENT : ADCT-701 is given through a tube attached to a needle inserted into a vein in the arm. PHASE : First-in-Human Phase I Trial STATUS : Recruiting SPONSOR : National Cancer Institute (NCI) DESCRIPTION: This is a first in human phase 1 study to test a new drug, ADCT-701, in people with Neuroendocrine neoplasms (NENs). ADCT-701 is an antibody drug conjugate (or ADC) that specifically targets "Delta Like Non-Canonical Notch Ligand 1" or DLK1, an antigen which has recently been found to be expressed on neuroendocrine cancers. The hope is this drug will suppress tumor growth, shrink tumors after tumor growth, and improve survival. *Note: This study includes all neuroendocrine neoplasms including neuroendocrine tumors, neuroendocrine carcinomas (i.e. "high grade neuroendocrine cancers"), pheochromocytoma, paraganglioma and adrenocortical carcinoma (ACC). For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : National Cancer Institute Medical Oncology Kimberley J Cooper EMAIL: kimberley.cooper@nih.gov PHONE: 240-858-5798 Principal investigator: Jaydira Del Rivero, M.D.,National Cancer Institute (NCI) LOCATIONS : National Instititues of Health Clinical Center: Bethesda, Maryland, United States 20892

Terms & Conditions INTRODUCTION These terms and conditions govern your use of this website. These terms and conditions of use are entered into by and between You and the Neuroendocrine Cancer Foundation (“Neuroendocrine Cancer Foundation” “I,” “we,” “us” and “our”). The following terms and conditions of use, together with any documents expressly incorporated by reference (collectively, these “Terms of Use”) govern your access to and use of the Website, its Content, its Social Media and our Apps. By using this website, you agree to be bound by and accept these terms and conditions in full. If you disagree with these terms and conditions or any part of these terms and conditions, you must not use this website. 1. THIS SITE DOES NOT PROVIDE MEDICAL ADVICE General The information contained on the www.neuroendocrinecancer.net website is for general information purposes only. The Neuroendocrine Cancer Foundation assumes no responsibility for errors or omissions in the contents on the Service. In no event shall Neuroendocrine Cancer Foundation be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Neuroendocrine Cancer Foundation reserves the right to make additions, deletions, or modifications to the contents on the Service at any time without prior notice. Informational & Educational Purposes Only The Neuroendocrine Cancer Foundation does not warrant that the website is free of viruses or other harmful components. The Site, Content and/or Services are intended for informational & educational purposes only and are not intended as professional medical advice. By accessing and using the Site and/or Services, such use shall constitute your agreement that the Site and/or Services is not professional medical advice and shall not be relied upon by you as such. Nothing in the content, products or services should be considered or used as a substitute for medical advice, diagnosis or treatment. This site and its services do not constitute the practice of any medical, nursing or other professional healthcare advice, diagnosis or treatment. You should always talk to your healthcare provider for diagnosis and treatment, including your specific medical needs. None of the products or services offered through this website represents or warrants that any particular service or product is safe, appropriate or effective for you. Always consult with your physician or another medical professional first before implementing any of our advice, information, or suggestions. Always consult with a physician or medical professional (not us) before implementing any changes to your diet, medication, lifestyle, exercise regimen, supplement regimen, or health practices. Please only implement any and all changes after consulting with your physician and assessing your own risk. Use of this Site or its Services does not constitute a patient-healthcare provider relationship. Users should always seek the advice of a physician or other qualified healthcare provider with any questions regarding personal health or medical conditions. Patients with healthcare related questions should call or see their physician or other healthcare provider promptly, and should not disregard professional medical advice, or delay seeking it, because of the Content. Never disregard professional medical advice or delay in seeking it because of something you have read on the Site! If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. If you are in the United States and are experiencing a medical emergency, please call 911 or call for emergency medical help on the nearest telephone. Information Is No Substitute for Professional Advice This Site contains only informational and educational material and information. The content on this Site is not a substitute for the advice of your attorney, physician, medical professional, mental health professional, financial advisor, accountant, or any other professional. Testimonials The Testimonials or examples on the Site are simply that: examples. While they are all accurate and authentic, we are not making any claims that you will experience the same or better results from using the Site and/or Services. External links disclaimer The Neuroendocrine Cancer Foundation website may contain links to external websites that are not provided or maintained by or in any way affiliated with the Neuroendocrine Cancer Foundation. Please note that the Neuroendocrine Cancer Foundation does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites. The mention of any product, service, organization, activity or therapy on the Website, Social Media or Apps should not be construed as the Neuroendocrine Cancer Foundation endorsement. 2. LICENSE TO USE WEBSITE Unless otherwise stated, the Neuroendocrine Cancer Foundation and/or its licensors own the intellectual property rights in the website and material on the website. Subject to the license below, all these intellectual property rights are reserved. You may view, download for caching purposes only, and print pages or other content from the website for your own personal use, subject to the restrictions set out below and elsewhere in these terms and conditions. You must not: Republish material from this website (including republication on another website); sell, rent or sub-license material from the website; show any material from the website in public; reproduce, duplicate, copy or otherwise exploit material on this website for a commercial purpose; edit or otherwise modify any material on the website; or redistribute material from this website except for content specifically and expressly made available for redistribution. Where content is specifically made available for redistribution, it may only be redistributed within your organization. Acceptable use You must not use this website in any way that causes, or may cause, damage to the website or impairment of the availability or accessibility of the website; or in any way which is unlawful, illegal, fraudulent or harmful, or in connection with any unlawful, illegal, fraudulent or harmful purpose or activity. You must not use this website to copy, store, host, transmit, send, use, publish or distribute any material which consists of (or is linked to) any spyware, computer virus, Trojan horse, worm, keystroke logger, rootkit or other malicious computer software. You must not conduct any systematic or automated data collection activities (including without limitation scraping, data mining, data extraction and data harvesting) on or in relation to this website without the Neuroendocrine Cancer Foundation's express written consent. You must not use this website to transmit or send unsolicited commercial communications. You must not use this website for any purposes related to marketing without the Neuroendocrine Cancer Foundation's express written consent. User content In these terms and conditions, “your user content” means material (including without limitation text, images, audio material, video material and audio-visual material) that you submit to this website, for whatever purpose. You grant to the Neuroendocrine Cancer Foundation a worldwide, irrevocable, non-exclusive, royalty-free license to use, reproduce, adapt, publish, translate and distribute your user content in any existing or future media. You also grant to the Neuroendocrine Cancer Foundation the right to sub-license these rights, and the right to bring an action for infringement of these rights. Your user content must not be illegal or unlawful, must not infringe any third party's legal rights, and must not be capable of giving rise to legal action whether against you or the Neuroendocrine Cancer Foundation or a third party (in each case under any applicable law). You must not submit any user content to the website that is or has ever been the subject of any threatened or actual legal proceedings or other similar complaints. The Neuroendocrine Cancer Foundation reserves the right to edit or remove any material submitted to this website, or stored on the Neuroendocrine Cancer Foundation’s servers, or hosted or published upon this website. Notwithstanding the Neuroendocrine Cancer Foundation’s rights under these terms and conditions in relation to user content, the Neuroendocrine Cancer Foundation does not undertake to monitor the submission of such content to, or the publication of such content on, this website. No warranties This website is provided “as is” without any representations or warranties, express or implied. The Neuroendocrine Cancer Foundation makes no representations or warranties in relation to this website or the information and materials provided on this website. Without prejudice to the generality of the foregoing paragraph, the Neuroendocrine Cancer Foundation does not warrant that: this website will be constantly available, or available at all; or the information on this website is complete, true, accurate or non-misleading. The mention of any product, service, organization, activity or therapy on the Website, Social Media or Apps should not be construed as a Neuroendocrine Cancer Foundation endorsement. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any legal, financial or medical matter you should consult an appropriate professional. Limitations of liability The Neuroendocrine Cancer Foundation assumes no responsibility for any injury or damage to persons or property arising out of or related to the Content, the Website, or the Apps. The Neuroendocrine Cancer Foundation will not be liable to you (whether under the law of contract, the law of torts or otherwise) in relation to the contents of, or use of, or otherwise in connection with, this website: to the extent that the website is provided free-of-charge, for any direct loss; for any indirect, special or consequential loss; or for any business losses, loss of revenue, income, profits or anticipated savings, loss of contracts or business relationships, loss of reputation or goodwill, or loss or corruption of information or data. These limitations of liability apply even if the Neuroendocrine Cancer Foundation has been expressly advised of the potential loss. Exceptions Nothing in this website disclaimer will exclude or limit any warranty implied by law that it would be unlawful to exclude or limit; and nothing in this website disclaimer will exclude or limit the Neuroendocrine Cancer Foundation’s liability in respect of any: death or personal injury caused by the Neuroendocrine Cancer Foundation’s negligence; fraud or fraudulent misrepresentation on the part of the Neuroendocrine Cancer Foundation; or matter which it would be illegal or unlawful for the Neuroendocrine Cancer Foundation to exclude or limit, or to attempt or purport to exclude or limit, its liability. Social Media Disclaimer By accessing, viewing and/or posting content to any Neuroendocrine Cancer Foundation Social Media Site on the internet, including but not limited to our blogs, Facebook, Twitter, Instagram, YouTube, and online forums, you accept, without limitation or qualification, the following terms of use, as well as any other terms of use required by the company that owns and operates the underlying social media site (e.g.,, any terms of use required by Facebook, Twitter, etc.). If you do not agree to the terms of this Policy, you may not view of post any content to any Neuroendocrine Cancer Foundation Social Media Site on the internet. Your use of Neuroendocrine Cancer Foundation Social Media Sites is acceptance of this Policy and has the same effect as if you had actually physically signed an agreement. Rules of Conduct DO NOT transmit materials in any manner that is unlawful, disruptive, threatening, profane, abusive, harassing, embarrassing, tortuous, defamatory, obscene, libelous, or is an invasion of another’s privacy, is hateful or racially, ethnically or otherwise objectionable as solely determined by the Neuroendocrine Cancer Foundation staff. DO NOT impersonate any person or entity or falsely state or otherwise misrepresent your affiliation with a person or entity. DO NOT transmit any unsolicited or unauthorized advertising, promotional materials, or any other form of solicitation. DO NOT transmit any materials that contain any kind of virus, spyware, or malware. DO NOT violate another’s copyright or intellectual property. DO NOT post any proprietary, confidential, sensitive, or nonpublic information. LACNETS RESERVES THE RIGHT TO (but is not obligated) to do any of the following: Moderate all content; Remove information, language, or any communication considered offensive and/or fails to conform with these terms of use; Edit or delete any communications posted on the Site or Social Media, regardless of whether such communications violate these standards; Block users who violate these guidelines. Exceptions Nothing in this website disclaimer will exclude or limit any warranty implied by law that it would be unlawful to exclude or limit; and nothing in this website disclaimer will exclude or limit the Neuroendocrine Cancer Foundation’s liability in respect of any: death or personal injury caused by the Neuroendocrine Cancer Foundation’s negligence; fraud or fraudulent misrepresentation on the part of the Neuroendocrine Cancer Foundation; or matter which it would be illegal or unlawful for the Neuroendocrine Cancer Foundation to exclude or limit, or to attempt or purport to exclude or limit, its liability. Reasonableness By using this website, you agree that the exclusions and limitations of liability set out in this website disclaimer are reasonable. If you do not think they are reasonable, you must not use this website. Other parties You accept that, as a limited liability entity, the Neuroendocrine Cancer Foundation has an interest in limiting the personal liability of its officers and employees. You agree that you will not bring any personal claim against the Neuroendocrine Cancer Foundation's officers or employees with respect to any losses you suffer in connection with the website. You agree that the limitations of warranties and liability set out in this website disclaimer will protect the Neuroendocrine Cancer Foundation’s officers, employees, agents, subsidiaries, successors, assigns and sub-contractors as well as the Neuroendocrine Cancer Foundation. Unenforceable provisions If any provision of this website disclaimer is, or is found to be, unenforceable under applicable law, that will not affect the enforceability of the other provisions of this website disclaimer. Indemnity You hereby indemnify the Neuroendocrine Cancer Foundation and undertake to keep the Neuroendocrine Cancer Foundation indemnified against any losses, damages, costs, liabilities and expenses (including without limitation legal expenses and any amounts paid by the Neuroendocrine Cancer Foundation to a third party in settlement of a claim or dispute on the advice of the Neuroendocrine Cancer Foundation’s legal advisers) incurred or suffered by the Neuroendocrine Cancer Foundation arising out of any breach by you of any provision of these terms and conditions, or arising out of any claim that you have breached any provision of these terms and conditions. Breaches of these terms and conditions Without prejudice to the Neuroendocrine Cancer Foundation’s other rights under these terms and conditions, if you breach these terms and conditions in any way, the Neuroendocrine Cancer Foundation may take such action as the Neuroendocrine Cancer Foundation deems appropriate to deal with the breach, including suspending your access to the website, prohibiting you from accessing the website, blocking computers using your IP address from accessing the website, contacting your internet service provider to request that they block your access to the website and/or bringing court proceedings against you. Variation The Neuroendocrine Cancer Foundation may revise these terms and conditions from time-to-time. Revised terms and conditions will apply to the use of this website from the date of the publication of the revised terms and conditions on this website. Please check this page regularly to ensure you are familiar with the current version. Assignment The Neuroendocrine Cancer Foundation may transfer, sub-contract or otherwise deal with the Neuroendocrine Cancer Foundation’s rights and/or obligations under these terms and conditions without notifying you or obtaining your consent. You may not transfer, sub-contract or otherwise deal with your rights and/or obligations under these terms and conditions. Severability If a provision of these terms and conditions is determined by any court or other competent authority to be unlawful and/or unenforceable, the other provisions will continue in effect. If any unlawful and/or unenforceable provision would be lawful or enforceable if part of it were deleted, that part will be deemed to be deleted, and the rest of the provision will continue in effect. Entire agreement These terms and conditions constitute the entire agreement between you and the Neuroendocrine Cancer Foundation in relation to your use of this website, and supersede all previous agreements in respect of your use of this website. The Neuroendocrine Cancer Foundation is also known as the Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS). You may contact the Neuroendocrine Cancer Foundation by email at info@neuroendocrinecancer.net . Disclaimer The information contained on the www.neuroendocrinecancer.net website is for general information purposes only. The Neuroendocrine Cancer Foundation assumes no responsibility for errors or omissions in the contents on the Service. In no event shall the Neuroendocrine Cancer Foundation) be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Neuroendocrine Cancer Foundation reserves the right to make additions, deletions, or modification to the contents on the Service at any time without prior notice. The Neuroendocrine Cancer Foundation does not warrant that the website is free of viruses or other harmful components. External links disclaimer The Neuroendocrine Cancer Foundation website may contain links to external websites that are not provided or maintained by or in any way affiliated with the Neuroendocrine Cancer Foundation. Please note that the Neuroendocrine Cancer Foundation does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites. Last updated February 17, 2025

Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs << Back Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT04750954 DRUG/TREATMENT: lutetium Lu-177 dotatate in combination with M3814 (peposertib) PHASE: 1b STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) Dr. Aman Chauhan discusses Lu-177 Dotatate + M3814 DESCRIPTION: This phase Ib trial is to find out the best dose, possible benefits and/or side effects of peposertib when given together with lutetium Lu-177 dotatate in treating patients with neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aman Chauhan, MD EMAIL: axc3268@med.miami.edu

Support Line The Neuroendocrine Cancer Foundation is collaborating with the Carcinoid Cancer Foundation (CCF) to provide Support Line assistance. The Neuroendocrine Cancer Foundation is here to help you and those affected by NET. If you are looking for more specific information than you have found on our resources page or virtual support offerings, please complete the following questionnaire* so we can provide more personalized support. Please allow us up to three business days to respond. We highly recommend reviewing and completing our NET VITALS tool to learn and share the most critical information about your or your loved one's NET diagnosis. *Please note, all patient information is kept strictly confidential and is only used to provide relevant resources. SUPPORT LINE QUESTIONNAIRE Scroll up after clicking 'submit' The Neuroendocrine Cancer Foundation does not substitute for medical advice, diagnosis, treatment or other healthcare services. The Neuroendocrine Cancer Foundation may provide information and connections to physicians, products, services, clinical trials or treatments related to neuroendocrine cancer, but the Neuroendocrine Cancer Foundation neither recommends nor endorses any particular healthcare institution or provider. Please consult your medical team about your individual care or treatment.